NCT07109375View on ClinicalTrials.gov

Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Fabry Disease

Interventions

DRUG

pegunigalsidase alfa

Pegunigalsidase alfa is 2 mg/mL concentrate for solution and is administered via intravenous infusion every two weeks.

Trial Locations (1)

Unknown

AOU Federico II, Dipartimento di Nefrologia, Napoli

All Listed Sponsors

lead

Chiesi Italia

INDUSTRY

NCT07109375 - Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting | Biotech Hunter | Biotech Hunter